Could the tachycardia in a patient with congenital hyperinsulinism on diazoxide who recently received furosemide be related to COVID-19 infection?

Tachycardia is More Likely Related to Furosemide Than COVID-19

The tachycardia in this patient is most likely a direct adverse effect of furosemide rather than a COVID-19-related complication. The FDA label for furosemide explicitly lists tachycardia as a sign of fluid or electrolyte imbalance that occurs during therapy 1. This mechanism is far more immediate and probable than post-acute sequelae of COVID-19 (PASC).

Why Furosemide is the Primary Culprit

Furosemide causes tachycardia through well-established mechanisms:

• Electrolyte depletion (particularly hypokalemia and hypomagnesemia) occurs commonly with furosemide therapy, especially with brisk diuresis 1
• Volume depletion from excessive diuresis leads to compensatory tachycardia as the body attempts to maintain cardiac output 1
• Hypotension from volume reduction triggers reflex tachycardia 1

The FDA label specifically warns that patients should be observed for tachycardia as a sign of fluid or electrolyte imbalance, alongside other symptoms like weakness, lethargy, muscle cramps, and hypotension 1.

Why COVID-19 is Less Likely

While COVID-19 can cause cardiovascular complications including tachycardia, several factors make this less probable:

Timing considerations: PASC-related tachycardia typically manifests as:

• Postural orthostatic tachycardia syndrome (POTS), defined by heart rate increase >30 bpm upon standing that lasts >30 seconds and is accompanied by symptoms 2
• Inappropriate sinus tachycardia that persists and doesn't slow at night 2
• Symptoms appearing weeks to months after acute infection as part of post-acute sequelae 2

The temporal relationship matters: If the tachycardia appeared shortly after furosemide administration in a patient already on diazoxide (which itself can cause fluid retention requiring diuretic therapy), the drug effect is the more parsimonious explanation.

Immediate Management Algorithm

1. Check electrolytes immediately: Measure potassium, magnesium, sodium, and assess volume status 1

2. Assess for volume depletion: Look for orthostatic vital signs, dry mucous membranes, decreased skin turgor, oliguria 1

3. Correct abnormalities: Replace electrolytes and adjust furosemide dose or temporarily discontinue if severe depletion is present 1

4. Monitor glucose closely: Both diazoxide and furosemide can affect glucose metabolism; furosemide may increase blood glucose levels 1

When to Consider COVID-19 as the Cause

Only pursue COVID-19 as the etiology if:

• Tachycardia persists after correcting electrolyte abnormalities and volume status
• Patient has documented recent COVID-19 infection with persistent symptoms
• Tachycardia is positional (meeting POTS criteria with >30 bpm increase on standing) 2
• Associated with other PASC symptoms like exercise intolerance, dyspnea, or chest pain not explained by other causes 2
• 10-minute active stand test demonstrates sustained inappropriate heart rate elevation 2

Critical Pitfall to Avoid

Do not attribute medication side effects to COVID-19 without first ruling out drug-related causes. Furosemide-induced tachycardia is common, predictable, and immediately reversible with appropriate management. Pursuing extensive COVID-19 cardiovascular workup before addressing the obvious medication effect wastes time and resources while the patient remains symptomatic from a correctable electrolyte/volume disturbance.

The combination of diazoxide (which causes sodium and fluid retention) and furosemide (given to counteract this retention) creates a setup for electrolyte-mediated tachycardia 1, 3. Address this first.